BMY
Bristol Myers Squibb · Health Care
4.5%
typical move (median |reaction| of last 8)
2026-10-29 pre · likely
next expected · estimated from pattern
12
scored events
Last eight reactions
2024-10-31 → 2026-07-30
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-07-30 | pre | +2.8% | 2.8% | -4.7% | -0.8% |
| 2026-04-30 | pre | +5.2% | 5.2% | -9.0% | -10.9% |
| 2026-02-05 | pre | +3.2% | 3.2% | +0.0% | +2.1% |
| 2025-10-30 | pre | +7.0% | 7.0% | +3.6% | +7.3% |
| 2025-07-31 | pre | -5.8% | 5.8% | +4.6% | +5.5% |
| 2025-04-24 | pre | +0.3% | 0.3% | -0.3% | -10.1% |
| 2025-02-06 | pre | -3.8% | 3.8% | -3.1% | +11.4% |
| 2024-10-31 | pre | +5.8% | 5.8% | -6.6% | +0.3% |
Source filings
2026-07-30 · 8-K press release
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook Strong Performance Underscores Growth Portfolio Momentum and Pipeline Progress • Second quarter reve
2026-04-30 · 8-K press release
Bristol Myers Squibb Reports First Quarter Financial Results for 2026 Financial Results Reflect Strong Execution and a Strengthened Foundation with Significant Pipeline Milestones Ahead • First quarte
2026-02-05 · 8-K press release
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025 Financial results reflect disciplined execution and focus on delivering long-term growth • Fourth quarter revenues
2025-10-30 · 8-K press release
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025 Performance Marked by Continued Growth Portfolio Momentum, Pipeline Advancements and Strategic Business Development • Third quarte
2025-07-31 · 8-K press release
Bristol Myers Squibb Reports Second Quarter Financial Results for 2025 Performance Underscores Continued Execution Against Long-Term Growth Strategy • Second quarter revenues were $12.3 billion ◦ Grow
2025-04-24 · 8-K press release
Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution • First quarter revenues were $11.2 billion , -6% (-
2025-02-06 · 8-K press release
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024 Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth • Fourth Quarter Revenues were $12.3 Bil
2024-10-31 · 8-K press release
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth • Third Qua